Zimmer Biomet

Alyve Medical, Inc. Appoints New CEO

Retrieved on: 
Wednesday, April 13, 2022
Technology, Medical Devices, FDA, Software, Other Health, Hardware, Health, General Health, Data Management, Board, Carpi, Zimmer Biomet, NMES, Medtronic, Health, Injury, Medicine, Vision restoration therapy, Leadership, General manager, FDA, Management, Quadram Institute

She succeeds John Winslow, who was the founding Chief Executive Officer and will continue on as Executive Vice President.

Key Points: 
  • She succeeds John Winslow, who was the founding Chief Executive Officer and will continue on as Executive Vice President.
  • Both Mr. Winslow and Ms. Bokelman will be members of the Alyve Medical Board of Directors.
  • She is the right leader for Alyve Medical as we accelerate broad commercialization in the U.S. and global expansion.
  • Alyve Medical Inc. is a novel medical technology company focused on reimagining the management of musculoskeletal care.

ZimVie to Report First Quarter 2022 Financial Results on May 5, 2022

Retrieved on: 
Tuesday, April 12, 2022
LinkedIn, Instagram, Life, Zimmer Biomet, GLOBE, Solution, Spine, Twitter, Dentistry, Facebook

WESTMINSTER, Colo., April 12, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022.

Key Points: 
  • WESTMINSTER, Colo., April 12, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022.
  • Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers, using conference ID: 3977855.
  • For more information about ZimVie, please visit us at www.ZimVie.com .

Robert Ronk joins nanoMAG® Medical Advisory Board

Retrieved on: 
Friday, April 8, 2022
Adoption, Polymer, Marketing, Multimedia, Zimmer Biomet, CMF, CEO, Sports medicine, MD, Plastic, LLC, Technology, George Washington University School of Medicine & Health Sciences, MAB, Washington University School of Medicine, Spine, University, Medical device

LIVONIA, Mich., April 8, 2022 /PRNewswire/ -- nanoMAG LLC, a medical device company that has developed a bioabsorbable magnesium alloy for use in a wide range of medical implants, is pleased to announce the appointment of Robert Ronk as the newest member of our Medical Advisory Board (MAB).

Key Points: 
  • LIVONIA, Mich., April 8, 2022 /PRNewswire/ -- nanoMAG LLC, a medical device company that has developed a bioabsorbable magnesium alloy for use in a wide range of medical implants, is pleased to announce the appointment of Robert Ronk as the newest member of our Medical Advisory Board (MAB).
  • Robert Ronk said, "Over my career, I have been fortunate to work on some groundbreaking innovative biomaterials.
  • Steve LeBeau, President of nanoMAG said, "nanoMAG is excited to have Rob add his years of experience in medical device product development to our MAB.
  • Kevin has spent his 25-year medical industry career in numerous executive leadership roles in marketing, sales, and business development in the United States and internationally at Stryker Medical.

Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute

Retrieved on: 
Tuesday, March 22, 2022
CMFT, Calcium sulfate, Podiatry, Society, NYSE, Trauma, Zimmer Biomet, Ankle, Foot, Pain, Quality of life, Genex Power, Surgeon, Sheep, Physician, Spine, 50/50 (2011 film), Patient, Infection, Pharmaceutical industry, Phosphorus, Dentistry

genex Bone Graft Substitute is a biphasic composite of exceptional purity that is specifically formulated tobalance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture1.

Key Points: 
  • genex Bone Graft Substitute is a biphasic composite of exceptional purity that is specifically formulated tobalance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture1.
  • genex Bone Graft Substitute's 50:50 biphasic composition of calcium sulfate and -tricalcium phosphate is not the only performance factor.
  • Michael Harris, Chief Executive Officer of Biocomposites, commented: "I am delighted we are partnering with Zimmer Biomet to deliver our new genex Bone Graft Substitute product to the U.S. market.
  • Bone healing response to a synthetic calcium sulfate/-tricalcium phosphate graft material in a sheep vertebral body defect model.

Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute

Retrieved on: 
Tuesday, March 22, 2022
CMFT, Calcium sulfate, Podiatry, Society, NYSE, Trauma, Zimmer Biomet, Ankle, Foot, Pain, Quality of life, Genex Power, Surgeon, Sheep, Physician, Spine, 50/50 (2011 film), Patient, Infection, Pharmaceutical industry, Phosphorus, Dentistry

KEELE, England, March 22, 2022 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, today announces that it has entered into a multi-year agreement with Zimmer Biomet (NYSE and SIX: ZBH), a global medical technology leader, to exclusively distribute genex Bone Graft Substitute with its new mixing system and delivery options in the U.S. orthopaedic market.

Key Points: 
  • - genex Bone Graft Substitute upgraded with a new closed-mixing system and a comprehensive set of delivery options for U.S. market
    - Zimmer Biomet will exclusively distribute genex Bone Graft Substitute in the U.S.
    KEELE, England, March 22, 2022 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, today announces that it has entered into a multi-year agreement with Zimmer Biomet (NYSE and SIX: ZBH), a global medical technology leader, to exclusively distribute genex Bone Graft Substitute with its new mixing system and delivery options in the U.S. orthopaedic market.
  • genex Bone Graft Substitute is a biphasic composite of exceptional purity that is specifically formulated tobalance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture1.
  • genex Bone Graft Substitute's 50:50 biphasic composition of calcium sulfate and -tricalcium phosphate is not the only performance factor.
  • Michael Harris, Chief Executive Officer of Biocomposites, commented: "I am delighted we are partnering with Zimmer Biomet to deliver our new genex Bone Graft Substitute product to the U.S. market.

Zimmer Biomet Announces Completion of ZimVie Spinoff

Retrieved on: 
Tuesday, March 1, 2022
Health, Compliance, Government, Risk, Intellectual property, Twitter, Growth, Security (finance), Theft, Annual report, Culture, COVID-19, Medication, Company, Zimmer Biomet, Private Securities Litigation Reform Act, NYSE, U.S. Securities and Exchange Commission, Dental, Artificial intelligence, Intention, Leadership, FDA, Life, Nasdaq, Forward-looking statement, Patient, Private sector, Solution, CEO, SEC

WARSAW, Ind., March 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that the Company has completed its spinoff of ZimVie, Zimmer Biomet's former Dental and Spine business.

Key Points: 
  • WARSAW, Ind., March 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that the Company has completed its spinoff of ZimVie, Zimmer Biomet's former Dental and Spine business.
  • "The spinoff of ZimVie marks a major milestone in the active portfolio management of Zimmer Biomet as we continue to strengthen our position as a global leader in the medtech space," said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet.
  • The spinoff was achieved through the distribution of80.3% of the shares of ZimVie to holders of Zimmer Biomet common stock on March 1, 2022, with Zimmer Biomet stockholders receiving one share of ZimVie common stock for every ten shares of Zimmer Biomet common stock held at the close of business on the record date of February 15, 2022.
  • Fractional shares of ZimVie common stock will not be distributed to Zimmer Biomet shareholders.

ZimVie Completes Separation from Zimmer Biomet; Announces Board of Directors

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Internal medicine, Board of directors, Nasdaq, Macdonald, McDonald's, Board, Twitter, Growth, Health policy, Form 10-K, Science, Industry, Company, IBM Global Services, Zimmer Biomet, NYSE, Gastrointestinal tract, Abcam, Hanger, Inc., Risk management, Senior, LinkedIn, News, Intention, Life, Instagram, Forward-looking statement, U.S. Securities and Exchange Commission, Solution, Informatics, PATH, SEC, Holding company, Management, LabCorp, Medtronic, Facebook, Dental, Insurance, Spine

This separation completes the path ZimVie began in 2021 when its former parent company announced its intention to separate its Dental and Spine businesses into one of the worlds newest and leading life sciences companies.

Key Points: 
  • This separation completes the path ZimVie began in 2021 when its former parent company announced its intention to separate its Dental and Spine businesses into one of the worlds newest and leading life sciences companies.
  • Asar brings executive and public company experience as well as significant experience in the healthcare products and services industry to ZimVies Board of Directors.
  • Mr. Jamali brings significant leadership experience and public company knowledge to ZimVies management team and Board of Directors.
  • Ms. Matusinec brings significant financial expertise and extensive experience in treasury, tax, insurance, shared services, and risk management to ZimVies Board of Directors.

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Retrieved on: 
Tuesday, February 15, 2022
Biotechnology, Medical Devices, Health, Nanotechnology, Technology, Intuitive Surgical, Patient, Quality of life, CEO, Company, Zimmer Biomet, Â, U.S. Securities and Exchange Commission, Solution, Security (finance), Dermatology, Nasdaq, CCO, Technology, Tufts University, Zimmer, Population, List of life sciences, Marketing, Employment, Engineering, Medtronic, Growth, Johnson & Johnson, NPS, Management, Medical imaging, Science

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer.
  • We are delighted to welcome Kevin to the Pulse Biosciences team and look forward to the impact he will have on expanding the commercial footprint for the CellFX System.
  • This team has done an incredible job developing a novel technology platform at the intersection of healthcare and technology that can address the needs of a broad patient population, said Kevin Danahy, Chief Commercial Officer of Pulse Biosciences.
  • In connection with his appointment as Chief Commercial Officer, Mr. Danahy has been granted stock options to purchase an aggregate of 300,000 shares of Company common stock.

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 14, 2022
NASDAQ, Patient, CEO, Company, Zimmer Biomet, Calendar, AES, Ablation, Commercial, American Epilepsy Society, Lists of diseases, Evo, FDA, Ageing, EDEN, NMTC, Seeg, Electrode, Medical device, Coal

Dave Rosa, CEO of NeuroOne commented, "During and subsequent to our fiscal first quarter, we made significant advancements across our product portfolio.

Key Points: 
  • Dave Rosa, CEO of NeuroOne commented, "During and subsequent to our fiscal first quarter, we made significant advancements across our product portfolio.
  • R&D expense in the first quarter of fiscal 2022 was$1.1 million, compared with$0.9 million in the same period of fiscal 2021.
  • SG&A expense in the first quarter of fiscal 2022 was$1.7 million, compared with$1.2 million in the prior year period.
  • Net loss was$2.8 millionfor the first quarter of fiscal 2022, compared to a net loss of$2.0 million in the first quarter of fiscal 2021.

Zimmer Biomet Announces Expected Completion Date of March 1, 2022 for Spinoff of ZimVie

Retrieved on: 
Monday, February 7, 2022
Board of directors, NASDAQ, Government, Private Securities Litigation Reform Act, ZBH, Artificial intelligence, Growth, Disclosure, Intellectual property, Culture, U.S. Securities and Exchange Commission, Forward-looking statement, Time, Date, Board, Solution, Intention, Vie, COVID-19, Twitter, Zimmer Biomet, Annual report, Leadership, EMEA, Investor relations, FDA, Regulation, Patient, Private sector, Security (finance), Compliance, NYSE, New, SEC, Life, Health, Dental, Organization, Theft, Regulation of tobacco by the U.S. Food and Drug Administration, Regulation Fair Disclosure, Food, Q&A, Risk, Public relations, Spine

As a result of the dividend, Zimmer Biomet shareholders will receive one share of ZimVie common stock for every ten shares of Zimmer Biomet common stock they hold on the Record Date.

Key Points: 
  • As a result of the dividend, Zimmer Biomet shareholders will receive one share of ZimVie common stock for every ten shares of Zimmer Biomet common stock they hold on the Record Date.
  • Immediately following the dividend, Zimmer Biomet will retain 19.7% of the outstanding shares of ZimVie common stock, which Zimmer Biomet intends to divest after the separation in a tax-efficient manner.
  • No action is required by Zimmer Biomet shareholders to receive the distributed shares of ZimVie common stock.
  • "When-issued" trading of ZimVie common stock is expected to begin on February 14, 2022, on NASDAQ, under the symbol "ZIMVV."